WO2000004050A3 - Neurotrophic growth factor - Google Patents

Neurotrophic growth factor Download PDF

Info

Publication number
WO2000004050A3
WO2000004050A3 PCT/EP1999/005031 EP9905031W WO0004050A3 WO 2000004050 A3 WO2000004050 A3 WO 2000004050A3 EP 9905031 W EP9905031 W EP 9905031W WO 0004050 A3 WO0004050 A3 WO 0004050A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
neurotrophic growth
bioprecursor
organism
derivative
Prior art date
Application number
PCT/EP1999/005031
Other languages
French (fr)
Other versions
WO2000004050A2 (en
Inventor
Hugo Alfonso Geerts
Stefan Leo Jozef Masure
Theo Frans Meert
Miroslav Cik
Donck Luc August Laurentiu Ver
Original Assignee
Janssen Pharmaceutica Nv
Hugo Alfonso Geerts
Stefan Leo Jozef Masure
Theo Frans Meert
Miroslav Cik
Donck Luc August Laurentiu Ver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000004050(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9815283.8A external-priority patent/GB9815283D0/en
Priority to PL348431A priority Critical patent/PL209952B1/en
Priority to CA2333910A priority patent/CA2333910C/en
Priority to EP05112473.3A priority patent/EP1640381B1/en
Priority to EP99938261.7A priority patent/EP1097167B2/en
Priority to JP2000560156A priority patent/JP4469500B2/en
Priority to AU52832/99A priority patent/AU768472B2/en
Priority to BR9912819-5A priority patent/BR9912819A/en
Priority to SK14-2001A priority patent/SK287361B6/en
Priority to DE69933771T priority patent/DE69933771T2/en
Priority to UA2001010334A priority patent/UA73922C2/en
Priority to IL14087799A priority patent/IL140877A0/en
Priority to HU0102821A priority patent/HU226073B1/en
Priority to BRPI9912819A priority patent/BRPI9912819B8/en
Priority to SI9930942T priority patent/SI1097167T1/en
Application filed by Janssen Pharmaceutica Nv, Hugo Alfonso Geerts, Stefan Leo Jozef Masure, Theo Frans Meert, Miroslav Cik, Donck Luc August Laurentiu Ver filed Critical Janssen Pharmaceutica Nv
Priority to DK99938261T priority patent/DK1097167T3/en
Publication of WO2000004050A2 publication Critical patent/WO2000004050A2/en
Publication of WO2000004050A3 publication Critical patent/WO2000004050A3/en
Priority to BG105107A priority patent/BG65518B1/en
Priority to NO20010212A priority patent/NO331809B1/en
Priority to HR20010036A priority patent/HRP20010036B1/en
Priority to HK02106928.2A priority patent/HK1045528B/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA

Abstract

There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in Figure 1, 21, 23 or 24 or encoding a functional equivalent, derivative or bioprecursor of said growth factor. The growth factor preferably comprises the amino acid sequence from position 27 to 139 of the sequence illustrated in Figure 1, or a functional equivalent, derivative or bioprecursor thereof. The nucleic acid molecule encoding enovin can be used to transform a host cell, tissue or organism by including it in an appropriate vector. The host cell, tissue or organism and the vector also form part of the invention.
PCT/EP1999/005031 1998-07-14 1999-07-14 Neurotrophic growth factor WO2000004050A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
IL14087799A IL140877A0 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor
DK99938261T DK1097167T3 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor
HU0102821A HU226073B1 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor
CA2333910A CA2333910C (en) 1998-07-14 1999-07-14 Neurotrophic growth factor
EP99938261.7A EP1097167B2 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor
JP2000560156A JP4469500B2 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor
AU52832/99A AU768472B2 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor
BR9912819-5A BR9912819A (en) 1998-07-14 1999-07-14 Neurotrophic growth factor
SK14-2001A SK287361B6 (en) 1998-07-14 1999-07-14 Human neurotrophic growth factor and use thereof
BRPI9912819A BRPI9912819B8 (en) 1998-07-14 1999-07-14 expression vector, transgenic microorganism, uses of a nucleic acid molecule and a neurotrophic growth factor, as well as pharmaceutical compositions comprising the same
UA2001010334A UA73922C2 (en) 1998-07-14 1999-07-14 Human neurotrophic growth factor (enovin), nucleic acid molecule coding it, vector, plasmid, pharmaceutical composition (variants), antibody, a method for revealing growth factor, set, a method for identification of agonist or antagonist (variants)
PL348431A PL209952B1 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor
EP05112473.3A EP1640381B1 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor
DE69933771T DE69933771T2 (en) 1998-07-14 1999-07-14 NEUROTROPHIC GROWTH FACTOR
SI9930942T SI1097167T1 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor
BG105107A BG65518B1 (en) 1998-07-14 2001-01-03 Neurotrophic growth factor
HR20010036A HRP20010036B1 (en) 1998-07-14 2001-01-12 Neurotrophic growth factor
NO20010212A NO331809B1 (en) 1998-07-14 2001-01-12 Neurotrophic growth factor
HK02106928.2A HK1045528B (en) 1998-07-14 2002-09-23 Neurotrophic growth factor

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9815283.8A GB9815283D0 (en) 1998-07-14 1998-07-14 Neurotrophic growth factor
GB9815283.8 1998-07-14
US24877299A 1999-02-12 1999-02-12
US09/248,772 1999-02-12
US32766899A 1999-06-08 1999-06-08
US09/327,668 1999-06-08

Publications (2)

Publication Number Publication Date
WO2000004050A2 WO2000004050A2 (en) 2000-01-27
WO2000004050A3 true WO2000004050A3 (en) 2000-11-09

Family

ID=27269394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/005031 WO2000004050A2 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor

Country Status (28)

Country Link
US (1) US7544788B2 (en)
EP (2) EP1640381B1 (en)
JP (2) JP4469500B2 (en)
KR (2) KR100712223B1 (en)
CN (1) CN1243770C (en)
AT (1) ATE343594T1 (en)
AU (1) AU768472B2 (en)
BG (1) BG65518B1 (en)
BR (2) BR9912819A (en)
CA (1) CA2333910C (en)
CY (1) CY1115496T1 (en)
CZ (1) CZ303868B6 (en)
DE (1) DE69933771T2 (en)
DK (2) DK1097167T3 (en)
ES (2) ES2479067T3 (en)
HK (2) HK1045528B (en)
HR (1) HRP20010036B1 (en)
HU (1) HU226073B1 (en)
ID (1) ID27024A (en)
IL (1) IL140877A0 (en)
NO (1) NO331809B1 (en)
NZ (1) NZ509723A (en)
PL (1) PL209952B1 (en)
PT (2) PT1640381E (en)
SI (1) SI1640381T1 (en)
SK (1) SK287361B6 (en)
TR (1) TR200100074T2 (en)
WO (1) WO2000004050A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969042B2 (en) 2004-08-19 2015-03-03 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
US9138461B2 (en) 2007-05-01 2015-09-22 Biogen Ma Inc. Compositions and methods for increasing vascularization

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
EA003734B1 (en) * 1998-07-06 2003-08-28 Нсджин А/С Neurotrophic factors
US7067473B1 (en) 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
SK287361B6 (en) * 1998-07-14 2010-08-09 Janssen Pharmaceutica N. V. Human neurotrophic growth factor and use thereof
US20020002269A1 (en) * 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
EP1867719A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
AU2002232785B2 (en) * 2000-12-22 2006-05-18 Genentech, Inc. Use of artemin, a member of the GDNF ligand family for preparing a neuroprotective medicament
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US20040077543A1 (en) * 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
NZ529126A (en) * 2001-03-28 2010-07-30 Biogen Idec Inc Use of neublastin polypeptides for treating allodynia, hyperalgesic pain and phantom pain
WO2003097051A2 (en) * 2002-05-17 2003-11-27 Merck Patent Gmbh Use of compounds that are effective as selective opiate receptor modulators
JP4571776B2 (en) * 2002-11-05 2010-10-27 Jx日鉱日石エネルギー株式会社 Lubricating oil composition
DE602004021648D1 (en) 2003-04-18 2009-07-30 Biogen Idec Inc Polymer-conjugated glycosylated neublastin
RU2005138368A (en) 2003-06-10 2006-07-27 ЭнЭсДЖЕНЕ А/С (DK) IMPROVED SECRETION OF NEUBLASTINE
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
DE602005022457D1 (en) * 2004-08-19 2010-09-02 Biogen Idec Inc Neublastin VARIATIONS
TWI501774B (en) 2006-02-27 2015-10-01 Biogen Idec Inc Treatments for neurological disorders
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
CN106890342B (en) 2007-02-06 2022-09-23 俞泰俊 Treatment and prevention of neurodegenerative diseases using gene therapy
WO2009002193A1 (en) * 2007-06-27 2008-12-31 Auckland Uniservices Limited Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
JO3462B1 (en) * 2012-08-22 2020-07-05 Regeneron Pharma Human Antibodies to GFR?3 and methods of use thereof
US11225689B2 (en) * 2016-08-17 2022-01-18 The Broad Institute, Inc. Method for determination and identification of cell signatures and cell markers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001815A2 (en) * 1998-07-06 2000-01-13 Nsgene A/S Neurotrophic factors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
SK287361B6 (en) * 1998-07-14 2010-08-09 Janssen Pharmaceutica N. V. Human neurotrophic growth factor and use thereof
US7067473B1 (en) * 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
US20020002269A1 (en) * 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor
WO2000034475A2 (en) 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
JP2002051906A (en) * 2000-08-11 2002-02-19 Nippon Platec Co Ltd Aluminum foil material capable of heating by ih cooker and aluminum foil material food container formed using the same
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US11162698B2 (en) 2017-04-14 2021-11-02 Johnson Controls Tyco IP Holdings LLP Thermostat with exhaust fan control for air quality and humidity control

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001815A2 (en) * 1998-07-06 2000-01-13 Nsgene A/S Neurotrophic factors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BALOH R H ET AL: "Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex.", NEURON, (1998 DEC) 21 (6) 1291-302., XP000857438 *
CREEDON D J ET AL: "Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 JUN 24) 94 (13) 7018-23., XP000882989 *
LIN L F ET AL: "GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons [see comments].", SCIENCE, (1993 MAY 21) 260 (5111) 1130-2., XP002914283 *
MASURE S ET AL: "Enovin, a member of the glial cell-line-derived neurotrophic factor (GDNF) family with growth promoting activity on neuronal cells. Existence and tissue-specific expression of different splice variants.", EUROPEAN JOURNAL OF BIOCHEMISTRY, (1999 DEC) 266 (3) 892-902., XP000882986 *
MILBRANDT J ET AL: "Persephin, a novel neurotrophic factor related to GDNF and neurturin.", NEURON, (1998 FEB) 20 (2) 245-53., XP000886826 *
SAARMA M ET AL: "Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF).", MICROSCOPY RESEARCH AND TECHNIQUE, (1999 MAY 15-JUN 1) 45 (4-5) 292-302. REF: 83, XP000885944 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969042B2 (en) 2004-08-19 2015-03-03 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
US9138461B2 (en) 2007-05-01 2015-09-22 Biogen Ma Inc. Compositions and methods for increasing vascularization

Also Published As

Publication number Publication date
US20050233359A1 (en) 2005-10-20
SK287361B6 (en) 2010-08-09
SI1640381T1 (en) 2014-07-31
SK142001A3 (en) 2002-02-05
JP4469500B2 (en) 2010-05-26
BG65518B1 (en) 2008-10-31
EP1640381B1 (en) 2014-05-14
AU5283299A (en) 2000-02-07
EP1097167B1 (en) 2006-10-25
ES2479067T3 (en) 2014-07-23
HU226073B1 (en) 2008-04-28
EP1097167A2 (en) 2001-05-09
HRP20010036B1 (en) 2010-06-30
IL140877A0 (en) 2002-02-10
NZ509723A (en) 2004-01-30
EP1640381A3 (en) 2007-01-31
PL209952B1 (en) 2011-11-30
EP1640381A2 (en) 2006-03-29
CA2333910C (en) 2016-11-15
CA2333910A1 (en) 2000-01-27
PT1640381E (en) 2014-07-17
CN1342165A (en) 2002-03-27
BRPI9912819B1 (en) 2018-09-18
ID27024A (en) 2001-02-22
ATE343594T1 (en) 2006-11-15
PT1097167E (en) 2007-02-28
KR20010083108A (en) 2001-08-31
KR20060061408A (en) 2006-06-07
BR9912819A (en) 2001-05-02
AU768472B2 (en) 2003-12-11
TR200100074T2 (en) 2001-11-21
HK1045528B (en) 2006-10-27
KR100712223B1 (en) 2007-04-27
ES2275349T3 (en) 2007-06-01
NO20010212L (en) 2001-03-14
BG105107A (en) 2001-10-31
JP2010158241A (en) 2010-07-22
CZ303868B6 (en) 2013-06-05
NO331809B1 (en) 2012-04-10
HUP0102821A2 (en) 2001-11-28
NO20010212D0 (en) 2001-01-12
PL348431A1 (en) 2002-05-20
EP1097167B2 (en) 2018-12-12
CZ200128A3 (en) 2001-08-15
CY1115496T1 (en) 2017-01-04
DE69933771T2 (en) 2007-09-13
HK1092477A1 (en) 2007-02-09
HK1045528A1 (en) 2002-11-29
JP2002520042A (en) 2002-07-09
CN1243770C (en) 2006-03-01
BRPI9912819B8 (en) 2021-05-25
HUP0102821A3 (en) 2003-09-29
DE69933771D1 (en) 2006-12-07
DK1640381T3 (en) 2014-07-14
WO2000004050A2 (en) 2000-01-27
KR100773776B1 (en) 2007-11-12
DK1097167T3 (en) 2007-03-12
JP4624476B2 (en) 2011-02-02
US7544788B2 (en) 2009-06-09
HRP20010036A2 (en) 2001-12-31

Similar Documents

Publication Publication Date Title
WO2000004050A3 (en) Neurotrophic growth factor
EP1832599A3 (en) Albumin fusion proteins
EP2277888A3 (en) Fusion proteins of albumin and erythropoietin
CA2253238A1 (en) Novel agouti-related gene
WO1998014592A3 (en) Telomerase reverse transcriptase
WO2003030821A3 (en) Albumin fusion proteins
WO2000053776A3 (en) Human kallikrein-like genes
WO1996034964A3 (en) Stable variant hk2 polypeptide
EP2172478A3 (en) Activity-dependent neurotrophic factor III (ADNF III)
WO2001042474A3 (en) Interferon-like molecules and uses thereof
WO2002012468A3 (en) 2,5-dkg permeases
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
WO2000000506A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
AU2043597A (en) Human taki dna encoding the same
WO1995034649A3 (en) Polycystic kidney disease 1 gene and uses thereof
WO2000004157A3 (en) Cloning and characterisation of novel mammalian peptidases
WO2002044379A3 (en) Transforming growth factor-beta-related molecules and uses thereof
WO2002046380A3 (en) Protein kinase
WO2002050116A3 (en) Adhesion molecule protein
WO2000061750A3 (en) TYROSINE KINASE SUBSTRATE (Tks) PROTEINS
WO2002034901A8 (en) Protein kinase
CA2242562A1 (en) Human dnase resistant to actin inhibition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99810884.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999938261

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1999 105107

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2001-28

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 142001

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2333910

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001/00330

Country of ref document: ZA

Ref document number: 200100330

Country of ref document: ZA

Ref document number: 2001/00074

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 560156

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 140877

Country of ref document: IL

Ref document number: P20010036A

Country of ref document: HR

Ref document number: 1020017000494

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000579

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00117/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 509723

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 52832/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999938261

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-28

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020017000494

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 52832/99

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020017000494

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1999938261

Country of ref document: EP